Viracta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Viracta Therapeutics

10/08/2022 14:00

* Viracta Therapeutics Inc  VIRX.OQ  reported a quarterly
adjusted
loss of 28 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Viracta Therapeutics Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Viracta Therapeutics Inc shares had fallen by 10.6% this
quarter and lost 4.9% so far this year.
    * The company reported a quarterly loss of $10.58 million.
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 01:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.30          -0.28          Beat
 Mar. 31 2022      -0.31          -0.28          Beat
 Dec. 31 2021      -0.43          -0.31          Beat
 Sep. 30 2021      -0.31          -0.40          Missed